Dr. Reddy's Q4 Results Preview: Biosimilars To Drive Revenue Growth
Dr. Reddy's Laboratories Ltd. is set to report its fourth-quarter earnings on May 9. The pharma major is expected to see net profit and revenue growth during the January-March period.
Revenue is estimated to rise 15% year-on-year to Rs 8,359.7 crore, according to consensus of analysts tracked by Bloomberg. While net profit is estimated to grow 11.37% to Rs 1,459 crore.
Ebitda is expected to jump 23.8% to Rs 2,268.6 crore, while margin is anticipated at 27.10%.
The company's revenue growth is primarily expected to be driven by the biosimilar pipeline and key launches in the Indian market. The domestic formulations business is also forecasted to be a significant contributor, with a projected 21% YoY growth, fueled by the integration of the Sanofi portfolio.
Dr. Reddy's Laboratories Q4 FY25 Preview (Consolidated YoY)
Revenue may rise 15.5% at Rs 8,359.7 crore.
Ebitda may rise 23.8% at Rs 2,268.6 crore.
Ebitda margin expected at 27.10%.
Net profit may rise 11.37% at Rs 1,459 crore.
While US sales are expected to grow, HDFC Securities predicts a more modest 3% YoY increase, driven by generic Revlimid sales, which will be partially offset by price and market share erosion in the base business, due to increased competition. The brokerage also noted a 4% quarter-on-quarter growth in the US business due to generic Revlimid sales.
Nuvama highlighted the vaccines business as a key driver of growth in India, and also sees potential benefits from New Respiratory Therapy products in the EU.
Both brokerages expect gross and Ebitda margins to remain steady.
What To Watch Out For
Investors will be keenly watching for updates on potential US launches over the next 12-18 months, as well as the performance of licenses and partnerships formed in recent years. These factors will be crucial in determining the company's growth trajectory in the near future.
Brokerage Views
US business to see 4% QoQ growth due to gRevlimid sales.
Growth will be partly offset by price and market share erosion in the base business, due to incremental competition in key products.
India to see 15% YoY growth on incremental sales from acquired vaccine business from Sanofi.
NRT business has been factored in.
Gross margin and Ebitda margin are expected to remain steady.
Vaccines business a key driver of growth in India.
Sees potential benefits from New Respiratory Therapy products in the EU.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
